Insider Trading in U.S. Stocks | Korro Bio disclosed 10 insider transactions on March 12

2026-04-11 03:38:06

On March 12, 2026, Korro Bio (KRRO) disclosed 10 insider trading transactions. Shareholder BASKETT FOREST, who owns more than 10%, bought 207.1k shares on March 10, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 12, 2026	Shareholder >10%	Behbahani Ali	March 10, 2026	Buy	207.1k	11.11	2.3M
March 12, 2026	Shareholder >10%	BASKETT FOREST, Chang Carmen, Florence Anthony A. Jr., Makhzoumi Mohamad, Mathers Edward T, New Enterprise Associates 17, L.P., SANDELL SCOTT D, Walker Paul Edward, Yang Rick	March 10, 2026	Buy	1.86M	11.11	20.71M
November 12, 2024	Executive	Agarwal Vineet	November 11, 2024	Buy	800	11.68	9,344.00
November 12, 2024	Executive	Agarwal Vineet	November 11, 2024	Sell	800	70.00	56k.00
October 18, 2024	Executive	Agarwal Vineet	October 17, 2024	Sell	164	73.71	11,700.00
October 18, 2024	Executive	Agarwal Vineet	October 17, 2024	Sell	23	77.00	1,771.00
October 18, 2024	Executive	Agarwal Vineet	October 17, 2024	Sell	260	77.55	20,130.00
October 18, 2024	Executive	Agarwal Vineet	October 17, 2024	Sell	115	74.56	8,574.50
October 18, 2024	Executive	Agarwal Vineet	October 17, 2024	Buy	9,263	11.68	108.2k.00
October 18, 2024	Executive	Agarwal Vineet	October 17, 2024	Buy	953	14.98	14.3k.00

【Company Information】

Korro Bio, Inc. was incorporated on November 13, 2014, in Delaware. The company is a biopharmaceutical firm whose mission is to discover, develop, and commercialize a new class of gene medicines based on editing RNA, enabling the treatment of rare and highly prevalent diseases. The company is building a differentiated pipeline of programs designed to leverage the body’s natural RNA editing process to achieve precise but transient single-base editing.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.